ADM2: A Protein with Potential as A Drug Target and Biomarker

Target Name: ADM2

NCBI ID: G79924

ADM2

ADM2: A Protein with Potential as A Drug Target and Biomarker

ADM2 (also known as dJ579N16.4) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the adaptor protein family, which plays a critical role in the process of protein-protein interactions and in the regulation of cellular signaling pathways.

One of the most interesting aspects of ADM2 is its potential as a drug target. The protein is known to interact with a variety of molecules, including the protein PDGF-B, which is a key signaling molecule in the development and maintenance of tissues. This interaction suggests that ADM2 may be a useful target for drugs that are designed to modulate PDGF-B signaling.

In addition to its potential as a drug target, ADM2 is also a potential biomarker for a variety of diseases. Its expression has been observed in a number of diseases, including cancer, neurodegenerative diseases, and kidney disease. This suggests that ADM2 may be a useful biomarker for these diseases, and that its levels may be able to be used as a diagnostic tool.

The study of ADM2 and its potential as a drug target and biomarker is an active area of research, with a number of studies exploring its role in various biological processes. For example, one study published in the journal Biochimica et Biophysica Acta (BBA) used ADM2 to investigate the effects of a drug on PDGF-B signaling in cancer cells. The results of the study showed that the drug had a significant effect on the level of PDGF-B in cancer cells, and that this effect was associated with an increase in the growth of the cells.

Another study published in the journal PLoS One used ADM2 to investigate the role of PDGF-B in the development of neurodegenerative diseases. The results of the study showed that the level of PDGF-B in the brains of individuals with neurodegenerative diseases was significantly higher than in individuals without these diseases, and that this was associated with an increase in the level of neurodegeneration.

In addition to its potential as a drug target and biomarker, ADM2 is also of interest to researchers as a potential therapeutic target for a variety of diseases. Its role in the regulation of PDGF-B signaling suggests that it may be a useful target for drugs that are designed to modulate this signaling pathway. For example, one study published in the journal Molecular Therapy found that ADM2 was a potential target for a drug that was being developed for the treatment of neurodegenerative diseases.

Overall, ADM2 is a protein that has a number of interesting properties and is being actively studied by researchers as a potential drug target and biomarker. Its interaction with PDGF-B and its potential as a therapeutic target make it an attractive candidate for further research. As research continues to advance, it is likely that the role of ADM2 in various biological processes will become increasingly clear, and its potential as a drug target and biomarker will continue to be explored.

Protein Name: Adrenomedullin 2

Functions: May play a role as physiological regulators of gastrointestinal, cardiovascular bioactivities mediated by the CALCRL/RAMPs receptor complexes. Activates the cAMP-dependent pathway

The "ADM2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ADM2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets